Drug Trial Radar · NCT03005288
Safety, Pharmacokinetics and Efficacy of Bimagrumab in Overweight and Obese Patients With Type 2 Diabetes
Last checked: Nov 19, 2026Latest source record: Jan 5, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
78
Actual
Start
Feb 1, 2017
Primary completion
Mar 21, 2019
Study completion May 8, 2019
Sponsor
- Lead sponsor
- Novartis PharmaceuticalsNovartis (NVS)
- Sponsor type
- Industry
- First posted
- Dec 29, 2016
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study assessed the safety, pharmacokinetics and efficacy of bimagrumab when administered in overweight and obese patients with type 2 diabetes
Conditions
- Diabetes Mellitus, Type 2
Interventions
BYM338 10 mg/kgDrug
intravenous infusion every four weeks
PlaceboOther
intravenous infusion every four weeks
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline in Total Body Fat Mass by Dual Energy X-ray Absorptiometry (DXA) at Week 48Time frame: Baseline, Week 48
Locations
9 sites in 2 countries. Site status is shown where the registry gives one.
Novartis Investigative Site
Anaheim, California
Novartis Investigative Site
Miami, Florida
Novartis Investigative Site
Miami, Florida
Novartis Investigative Site
Miami Lakes, Florida
Novartis Investigative Site
Orlando, Florida
Novartis Investigative Site
Baton Rouge, Louisiana
Novartis Investigative Site
Berlin, New Jersey
Novartis Investigative Site
Eatontown, New Jersey
Novartis Investigative Site
Merthyr Tydfil, Mid Glamorgan, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.